Peter Pekos
Director/Board Member at CARDIOL THERAPEUTICS INC.
Net worth: 845 795 $ as of 2024-03-30
Profile
Peter Pekos is the founder of Dalton Chemical Laboratories, Inc. where he holds the title of President & Chief Executive Officer since 1986.
He is also the founder of Ashbury Biologicals, Inc., Jupiter Consumer Products Ltd.
Mr. Pekos's current jobs include being an Independent Director at Cardiol Therapeutics, Inc., a Director at Diamond Therapeutics, Inc., and a Member-Editorial Board at Biotechnology Focus.
Mr. Pekos's former job was as Chairman at ventureLAB from 2011 to 2020.
Mr. Pekos received his undergraduate degree from the University of Toronto in 1983 and his graduate degree from York University in 1986.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2024-02-28 | 467,290 ( 0.72% ) | 845 795 $ | 2024-03-30 |
Peter Pekos active positions
| Companies | Position | Start |
|---|---|---|
| CARDIOL THERAPEUTICS INC. | Director/Board Member | 2017-12-14 |
Dalton Chemical Laboratories, Inc.
 Dalton Chemical Laboratories, Inc. Chemicals: Major DiversifiedProcess Industries Dalton Chemical Laboratories, Inc. engages in the provision of integrated drug discovery, development and manufacturing services. Its products include building blocks, glitazones, labelled compounds, natural compounds, peptides, steroids and controlled drugs. The firm also offers formulation development, flow chemistry, conjugation and contract research services. The company was founded by Peter Pekos in 1986 and is headquartered in Toronto, Canada. | Chief Executive Officer | 1985-12-31 |
| Biotechnology Focus | Corporate Officer/Principal | - |
Diamond Therapeutics, Inc.
 Diamond Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Diamond Therapeutics, Inc. is a Canadian clinical-stage drug development company founded in 2018 by Judy Blumstock. The company is based in an undisclosed location and is focused on developing safe, FDA, EMA, and Health Canada approved therapies for neuropsychiatric conditions. The company is developing sub-perceptual, non-hallucinogenic, psychedelic-based treatments that hold potential for use across a broad patient cohort, with the goal of maximizing the positive impact better drugs can have on the mental health crisis. Diamond's mission is to develop new and better therapies for mental health conditions by unlocking the promise of psychedelic compounds. | Director/Board Member | - |
Former positions of Peter Pekos
| Companies | Position | End |
|---|---|---|
Venturelab
 Venturelab Miscellaneous Commercial ServicesCommercial Services ventureLAB provides business development solutions. Its programs focuses on capital, talent, technology, and customers. The company is headquartered in Markham, Canada. | Chairman | 2019-12-31 |
| Jupiter Consumer Products Ltd. | Founder | - |
| Ashbury Biologicals, Inc. | Founder | - |
Training of Peter Pekos
| York University | Graduate Degree |
| University of Toronto | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| CARDIOL THERAPEUTICS INC. | Health Technology |
| Private companies | 6 |
|---|---|
Dalton Chemical Laboratories, Inc.
Dalton Chemical Laboratories, Inc. Chemicals: Major DiversifiedProcess Industries Dalton Chemical Laboratories, Inc. engages in the provision of integrated drug discovery, development and manufacturing services. Its products include building blocks, glitazones, labelled compounds, natural compounds, peptides, steroids and controlled drugs. The firm also offers formulation development, flow chemistry, conjugation and contract research services. The company was founded by Peter Pekos in 1986 and is headquartered in Toronto, Canada. | Process Industries |
| Ashbury Biologicals, Inc. | |
| Jupiter Consumer Products Ltd. | |
| Biotechnology Focus | |
Venturelab
Venturelab Miscellaneous Commercial ServicesCommercial Services ventureLAB provides business development solutions. Its programs focuses on capital, talent, technology, and customers. The company is headquartered in Markham, Canada. | Commercial Services |
Diamond Therapeutics, Inc.
Diamond Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Diamond Therapeutics, Inc. is a Canadian clinical-stage drug development company founded in 2018 by Judy Blumstock. The company is based in an undisclosed location and is focused on developing safe, FDA, EMA, and Health Canada approved therapies for neuropsychiatric conditions. The company is developing sub-perceptual, non-hallucinogenic, psychedelic-based treatments that hold potential for use across a broad patient cohort, with the goal of maximizing the positive impact better drugs can have on the mental health crisis. Diamond's mission is to develop new and better therapies for mental health conditions by unlocking the promise of psychedelic compounds. | Health Technology |
- Stock Market
- Insiders
- Peter Pekos